Targeting CXCR2 has been shown to synergize with ICB in multiple preclinical models of KRAS-mutant colorectal cancer and PDAC (28, 30, 85), providing a potential combination therapy for the treatment of KRAS-mutant patients with cancer in the clinic. Here, KRAS is linked to colorectal cancer.